Special Issue

Recent Advances in Amorphous Solid Dispersions: Preformulation, Formulation Strategies, Technological Advancements and Characterization

Message from the Guest Editors

The majority of new chemical entities in development are crystalline in nature, and thus suffer from poor solubility and bioavailability. Over the last two decades, amorphous solid dispersions (ASDs) have been utilized as a promising technology to improve the solubility and bioavailability of poorly soluble drugs, thus attending to unmet therapeutic needs with poorly soluble drugs. Recent advances pertinent to ASDs elucidate novel manufacturing technologies, chemical modifications of polymers, improvised manufacturing, and characterization techniques in pharmaceutical applications. Suitable topics for submission include, but are not limited to, the following:

- Formulating high-drug-load ASDs;
- Novel techniques in manufacturing ASDs;
- Characterization of ASDs:
- Preformulation and material sparing techniques for ASDs:
- Role of ASDs in navigating molecules from bench to market;
- Risk assessment and QBD-based formulation development of ASDs;
- Overcoming the manufacturing and scale-up challenges of ASDs;
- Downstream processing of ASDs;
- Application of lipids, surfactants, and mesoporous silica in conjunction with ASDs

Guest Editors

Dr. Pavan Kumar Nukala

College of Pharmacy and Health Sciences, St. John's University, Queens, NY 11439, USA

Dr. Pradeep Kumar Bolla

Department of Biomedical Engineering, College of Engineering, The University of Texas at El Paso, El Paso, TX 79968, USA



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/214967

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

